KINS Form 144 Filed for 5,000-Share Sale via Merrill on 09/03/2025
Rhea-AI Filing Summary
Kingstone Companies, Inc. (KINS) submitted a Form 144 notice for a proposed sale of common stock. The filing lists a broker as Merrill (225 Liberty Street, New York, NY) and shows an intended sale of 5,000 shares of common stock on or about 09/03/2025 with an aggregate market value of $80,000, and 14,140,604 shares outstanding. The securities being offered were acquired largely through stock grants from Kingstone Companies, Inc. on dates in 2020 and 2022, with specific grant amounts of 112, 1,913, 667 and 1,208 shares identified. The filer states there were no securities sold in the past three months and signs the standard representation regarding material nonpublic information.
Positive
- Filer provided clear transaction details including broker name, number of shares (5,000), aggregate value ($80,000), and approximate sale date (09/03/2025).
- Acquisition provenance disclosed with acquisition dates and amounts showing the shares originated from company stock grants in 2020 and 2022.
- No sales in past three months is explicitly reported.
Negative
- None.
Insights
TL;DR: Routine Form 144 disclosing a proposed small sale of common stock via Merrill with acquisition via company stock grants.
The filing documents a planned disposition of 5,000 common shares through Merrill with an indicated aggregate market value of $80,000 and identifies the acquisition dates and amounts as company stock grants in 2020 and 2022. The notice states no sales in the prior three months and includes the required representation about material nonpublic information. For investors, this is a disclosure of an insider/affiliate intent to sell rather than operational or financial performance information.
TL;DR: Form 144 filing is a procedural disclosure consistent with Rule 144 sale requirements; it contains acquisition provenance for the shares to be sold.
The document lists the origin of the shares as stock grants from the issuer with acquisition dates and quantities, meeting Rule 144 disclosure expectations. It names the broker and an approximate sale date. The filing includes the signer’s attestation regarding knowledge of material adverse information. This is a compliance-focused disclosure rather than a corporate governance change or event.